Sofosbuvir is a medicine used to manage hepatitis C. Disabling the virus's ability to reproduce, the ingredient helps clear the infection from the liver and supports long-term organ restoration.
When the body fights hepatitis C, a key component works to stop the virus from copying itself. Sofosbuvir belongs to a class called nucleotide-analogue antivirals. These medicines act like a piece of the virus’s genetic code, tricking the virus and preventing it from reproducing.
In Singapore, Sofosbuvir is the active compound found in several approved treatments, such as Sovaldi, Harvoni and Velpanat. By targeting the hepatitis C virus directly, it helps reduce the amount of virus in the bloodstream, which can lessen liver inflammation over time.
Because it works against many hepatitis C genotypes, clinicians often consider it when planning therapy for adults with chronic infection. The medication is taken orally, making it a convenient option compared with injectable antivirals.
Patients in Singapore may encounter Sofosbuvir as part of several approved treatments. Commercial products that include this ingredient are Sovaldi (tablet), Harvoni (tablet combining Sofosbuvir with ledipasvir) and Velpanat (tablet combined with velpatasvir). Each is available as a solid oral dosage, packaged in blister packs that protect the tablets from moisture.
Both brand-name and generic versions are regulated by the Health Sciences Authority, ensuring that the amount of Sofosbuvir in each tablet meets local standards. While the brand names differ, the underlying active ingredient remains the same, delivering the intended antiviral effect.
Chronic hepatitis C infection is the primary condition that Sofosbuvir-based regimens aim to control. The medication is also used in patients with different viral genotypes, ranging from genotype 1 to genotype 6, because it works across these variations.
People who have progressed to liver fibrosis or early cirrhosis may benefit from Sofosbuvir-containing therapy, as reducing viral load can slow further liver damage.
In some cases, Sofosbuvir is part of combination therapy for patients co-infected with HIV, where coordinated antiviral strategies are needed.
By mimicking a building block of viral RNA, this compound interferes with the virus’s ability to copy its genetic material. When the hepatitis C virus tries to replicate, the mimic is incorporated into the viral chain, causing premature termination of the process.
The result is a drop in the amount of virus circulating in the blood, giving the immune system a better chance to clear the infection. This action does not rely on the host’s liver enzymes, which helps limit many common medication-related side effects.
Mild fatigue, headache and occasional nausea are frequently reported by people taking Sofosbuvir-based medicines. These symptoms usually resolve on their own within a few days.
Rarely, patients may experience severe liver injury, marked by yellowing of the skin or dark urine. Anaphylactic-type allergic reactions, such as swelling of the face or difficulty breathing, also require urgent medical attention.
Women who are pregnant or may become pregnant should avoid Sofosbuvir-containing regimens unless a specialist determines the benefits outweigh the risks. Individuals with known hypersensitivity to Sofosbuvir or any component of the tablet should not use these medicines.
Alcohol use can increase liver strain, so readers should check the medication package for guidance on alcohol consumption. Some drugs that affect liver enzymes, such as certain antiretrovirals or immunosuppressants, may alter Sofosbuvir levels; the labeling provides detailed interaction information.
Storing these medicines away from moisture and heat helps keep them effective throughout the treatment course. Typical therapy lasts 12 weeks, though shorter or longer durations may be prescribed based on viral genotype and liver condition.
For detailed usage, dosing, and administration, refer to the specific medication's clinical information.
This article provides an educational overview of Sofosbuvir and is not medical advice. Medicines containing this ingredient-including Sovaldi, Harvoni and Velpanat-may differ in formulation, strength, and directions. The information here does not replace personalized clinical guidance, and the author accepts no liability for any decisions made based on this content. Readers should review the labeling of their specific medication and seek guidance from a healthcare professional.
Additional reliable details can be found at the following links:
